Dr. Vivek A Saraswat
Dr. Karan Kumar |
09.03.2026 |
Nor-ursodeoxycholic acid for metabolic dysfunction-associated steatotic liver disease: is there enough evidence for clinical use? A critique of a phase III trial and regulatory endorsement of the drug |
|
|
10.1016/j.jceh.2026.103536 |
| Dr. Vivek A Saraswat |
Feb, 2026 |
Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure. |
20 |
1 |
View Link |
Dr. Vivek A Saraswat
Dr. Karan Kumar |
23.01.2026 |
Clinical Profile and Prognostic Predictors in Hepatitis A Virus–Induced Acute Liver Failure |
|
|
10.1016/j.jceh.2026.103471 |
| Dr. Karan Kumar |
Jan, 2025 |
Impact of <scp>Karnofsky</scp> performance status on outcomes of patients with severe alcohol‐associated hepatitis: a propensity‐matched analysis |
55 |
1 |
10.1111/imj.16562 |
| Dr. Karan Kumar |
Feb, 2025 |
Current status of etiology and outcomes of acute liver failure in India—A multicentre study from tertiary centres |
44 |
1 |
10.1007/s12664-024-01634-x |
Dr. Vivek A Saraswat
Dr. Karan Kumar |
Feb, 2025 |
Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia |
19 |
1 |
10.1007/s12072-024-10773-4 |
Dr. Vivek A Saraswat
Dr. Karan Kumar |
Feb, 2025 |
Current status of etiology and outcomes of acute liver failure in India—A multicentre study from tertiary centres |
44 |
1 |
View Link |
| Vivek A Saraswat |
01.03.2025 |
Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes |
19 |
3 |
View Link |
| Dr. Karan Kumar |
May 2025 |
Infections in Standard or Tapered Dose of Prednisolone for Alcohol-Associated Hepatitis: A Randomized Trial (STASH Trial) |
10 |
4309 |
10.14309/ajg.0000000000003416 |
Dr. Vivek A Saraswat
Dr. Kumar Kumar |
01.07.2025 |
Predictors of Non-response to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma: A Multicentre Real World Study (HCC-AB Study) |
15 |
4 |
10.1016/j.jceh.2025.102513 |
Dr. Vivek A Saraswat
Dr. Kumar Kumar |
01.07.2025 |
Evaluation of Controlled Attenuation Parameter as a Tool for Assessment of Hepatic Steatosis in Living Liver Donors |
15 |
4 |
10.1016/j.jceh.2025.102514 |
| Vivek A Saraswat |
01.07.2025 |
Utility of Transient Elastography in Differentiating Biliary Atresia from Other Causes of Neonatal Cholestasis: A Prospective Observational Study |
15 |
4 |
View Link |
Dr. Karan Kumar
Dr. Vivek A Saraswat |
01.09.2025 |
Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025 |
15 |
5 |
10.1016/j.jceh.2025.102547 |
| Vivek A Saraswat |
01.09.2025 |
Indian National Association for the Study of Liver (INASL) Guidance Statements for Determining Futility in Liver Transplantation |
15 |
5 |
View Link |
| Vivek A Saraswat |
01.09.2025 |
Adoption of the new nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD |
15 |
5 |
View Link |
| Dr. Karan Kumar |
27.10.2025 |
Therapeutic Options for Alcohol-Associated Hepatitis in Resource-Limited Settings |
24 |
1 |
10.1007/s11901-025-00709-3 |
| Dr. Vivek A Saraswat |
01.11.2025 |
Indian National Association for the Study of the Liver Position Statements on Prevention, Diagnosis, and Management of Hepatitis B Virus Infection in India |
15 |
6 |
View Link |
Dr. Karan Kumar
Dr. Vivek A Saraswat |
Dec, 2025 |
From guidelines to practice: Evaluating real-world adherence and knowledge-attitude–practice in HBV mother-to-child transmission prevention |
1 |
2 |
10.1007/s12664-025-01933-x |
| Dr. Karan Kumar |
01.01.2024 |
Long Term HBsAg Responses to Peg-Interferon Alpha-2b in HBeAg Negative Chronic Hepatitis B Patients Developing Clinical Relapse after Stopping Long-Term Nucleos(t)ide Analogue Therapy |
14 |
1 |
10.1016/j.jceh.2023.08.008 |
| Dr. Karan Kumar |
01.01.2024 |
2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations |
14 |
1 |
10.1016/j.jceh.2023.08.005 |
| Vivek A Saraswat |
April, 2024 |
Early Diagnosis of Gall Bladder Cancer: An Appeal. |
14 |
2 |
View Link |
Vivek A Saraswat
Karan Kumar |
April, 2024 |
Transforming lives: A triumph of public‐private partnership in successful liver transplants. |
43 |
527-529 |
View Link |
Dr. Karan Kumar
Dr. Vivek A Saraswat |
Apr, 2024 |
Transforming lives: A triumph of public-private partnership in successful liver transplants |
43 |
2 |
10.1007/s12664-024-01564-8 |
Dr. Karan Kumar
Dr. Vivek A Saraswat |
Mar, 2024 |
Impact of Gender discordance on Outcomes in Living Donor Liver Transplantation |
13 |
7 |
10.36106/paripex |
| Dr. Karan Kumar |
01.05.2023 |
Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN. |
2 |
04 |
10.1097/hc9.0000000000000098 |
| Vivek A Saraswat |
Jun 2023 |
Position statement from the Indian Society of Gastroenterology, Cardiological Society of India, Indian Academy of Neurology and Vascular Society of India on gastrointestinal bleeding and endoscopic procedures in patients on antiplatelet and /or anticoagulant theraphy |
42 |
3 |
View Link |
| Dr. Karan Kumar |
15.06.2023 |
Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure |
10 |
|
10.3389/fmed.2023.1060073 |
| Dr. Karan Kumar |
01.07.2023 |
Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience |
13 |
4 |
10.1016/j.jceh.2023.02.003 |
| Dr. Karan Kumar |
01.09.2023 |
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis |
63 |
|
10.1016/j.eclinm.2023.102179 |
| Dr. Karan Kumar |
01.11.2023 |
Role of Prophylactic Antibiotics in Patients with Severe Alcohol-related Hepatitis |
13 |
6 |
10.1016/j.jceh.2023.06.012 |